Table 3.
Clinical and economic outcomes for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence (discounted by 3%)
| Outcomes | CAZ-AVI sequencea | Ceftolozane/Tazobactam sequenceb |
|---|---|---|
| % of patients with cure | 93.04% | 91.52% |
| % of patients died in hospital | 5.02% | 5.60% |
| % of patients with AE | 6.12% | 7.48% |
| Average number of days in hospital | 13.04 | 13.42 |
| LYs | 4.411 | 4.384 |
| QALYs | 4.021 | 3.982 |
| Drug costs | € 2952 | € 2324 |
| Hospitalisation costs | € 11,355 | € 11,781 |
| SAE costs | € 185 | € 226 |
| Recurrence costs | € 0 | € 0 |
| Total costs | € 14,492 | € 14,331 |
| Incremental cost per QALY gained | € 4099 | |
AE = adverse event; CAZ-AVI = ceftazidime-avibactam; LY = life year; QALY = quality-adjusted life year; SAE = serious adverse event.
aCAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem
bCeftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem